benzimidazole has been researched along with pyrazole in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Kulys, J; Tetianec, L; Ziemys, A | 1 |
| Abdullah, MM; Bakht, MA; Majeed, J; Shaharyar, M | 1 |
| Cheng, HB; Guo, J; Li, WJ; Ren, TG; Yang, LR; Zhang, JL | 1 |
| Huynh, HV; Sivaram, H; Tan, J | 1 |
| Abdelgawad, MA; Bakr, RB; Omar, HA | 1 |
| Abdel-Halim, AH; Ali, HI; Ali, MM; Attia, YM; El Abd, YS; El Diwani, HI; El-Shenawy, R; Fyiad, AA; Galal, SA; Khairat, SHM; Mahmoud, AE; Ramdan, R; Shouman, SA; Tabll, A | 1 |
| Liu, CH; Shi, TQ; Wang, YT; Zhu, HL | 1 |
| Akter, M; Debono, CO; Devine, SM; Drew, SC; Drinkwater, N; Krishnarjuna, B; MacRaild, CA; McGowan, S; Norton, RS; Scammells, PJ; Scanlon, MJ; Wang, G | 1 |
| Ahmad, M; Ashfaq, UA; Aslam, S; Ibraheem, F; Khan, ZA; Sultan, S | 1 |
| Dubiel, K; Dzwonek, K; Hucz-Kalitowska, J; Lamparska-Przybysz, M; Lipner, J; Magdycz, M; Olejkowska, P; Pieczykolan, J; Piórkowska, N; Popiel, D; Stańczak, A; Stańczak, PS; Wieczorek, M; Yamani, A; Zdżalik-Bielecka, D | 1 |
| Carter, DM; Dudaniec, K; Gohlke, U; Heinemann, U; Małecki, PH; Nazaré, M; Przygodda, J; Specker, E; Weiss, MS | 1 |
1 review(s) available for benzimidazole and pyrazole
| Article | Year |
|---|---|
Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3).
Topics: Antineoplastic Agents; Benzimidazoles; Cell Proliferation; Drug Discovery; Humans; Protein Kinase Inhibitors; Pyrazoles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3 | 2021 |
10 other study(ies) available for benzimidazole and pyrazole
| Article | Year |
|---|---|
Probing Aspergillus niger glucose oxidase with pentacyanoferrate(III) aza- and thia-complexes.
Topics: Aspergillus niger; Benzimidazoles; Ferric Compounds; Glucose Oxidase; Histidine; Imidazoles; Models, Chemical; Models, Molecular; Oxidation-Reduction; Pyrazoles; Pyridines; Structure-Activity Relationship; Thiadiazoles; Triazoles | 2006 |
Pyrazoline bearing benzimidazoles: search for anticancer agent.
Topics: Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Discovery; Humans; Pyrazoles | 2010 |
Synthesis of benzimidazoles containing pyrazole group and quantum chemistry calculation of their spectroscopic properties and electronic structure.
Topics: Absorption; Benzimidazoles; Electrons; Models, Molecular; Molecular Conformation; Pyrazoles; Quantum Theory; Spectrum Analysis | 2012 |
Cationic gold(I) heteroleptic complexes bearing a pyrazole-derived N-heterocyclic carbene: syntheses, characterizations, and cytotoxic activities.
Topics: Benzimidazoles; Cell Line, Tumor; Cell Survival; Coordination Complexes; Gold; Heterocyclic Compounds; Humans; Ligands; Methane; Molecular Conformation; Pyrazoles | 2013 |
Design, synthesis and biological evaluation of some novel benzothiazole/benzoxazole and/or benzimidazole derivatives incorporating a pyrazole scaffold as antiproliferative agents.
Topics: Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Benzoxazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Pyrazoles; Structure-Activity Relationship | 2017 |
Part II: New candidates of pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 2; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Pyrazoles; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2018 |
Synthesis, biological evaluation and molecular docking of benzimidazole grafted benzsulfamide-containing pyrazole ring derivatives as novel tubulin polymerization inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HEK293 Cells; Hepatocytes; Humans; Mice; Molecular Docking Simulation; Molecular Structure; Polymerization; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Tubulin; Tubulin Modulators | 2019 |
Identification of the Binding Site of Apical Membrane Antigen 1 (AMA1) Inhibitors Using a Paramagnetic Probe.
Topics: Amino Acid Sequence; Antigens, Protozoan; Benzimidazoles; Binding Sites; Cell Membrane; Crystallography, X-Ray; Furans; Hydrophobic and Hydrophilic Interactions; Ligands; Magnetic Resonance Spectroscopy; Membrane Proteins; Models, Molecular; Molecular Probes; Molecular Structure; Peptides; Protein Binding; Protozoan Proteins; Pyrazoles; Pyrimidines; Pyrroles; Quinazolinones; Structure-Activity Relationship; Sulfonamides | 2019 |
Synthesis, molecular docking and anti-diabetic studies of novel benzimidazole-pyrazoline hybrid molecules.
Topics: Benzaldehydes; Benzimidazoles; Chalcones; Hydrazines; Hypoglycemic Agents; Molecular Docking Simulation; Pyrazoles; Structure-Activity Relationship | 2020 |
Enhanced Properties of a Benzimidazole Benzylpyrazole Lysine Demethylase Inhibitor: Mechanism-of-Action, Binding Site Analysis, and Activity in Cellular Models of Prostate Cancer.
Topics: Benzimidazoles; Binding Sites; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Jumonji Domain-Containing Histone Demethylases; Models, Molecular; Molecular Structure; Pyrazoles; Structure-Activity Relationship; Tumor Cells, Cultured | 2021 |